The iFuse Implant System® is intended for sacroiliac fusion for the following conditions:
Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.
To augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.
Acute, nonacute, and nontraumatic fractures involving the sacroiliac joint.

If present, a pelvic fracture should be stabilized prior to the use of iFuse implants.

Healthcare professionals should refer to the Instructions For Use for indications, contraindications, warnings, and precautions at www.sibone.com/label.

There are potential risks associated with iFuse procedures. They may not be appropriate for all patients and all patients may not benefit. For information about the risks, visit http://sibone.com/risks

SIBONE and iFuse Implant System are registered trademarks, and Sacropelvic Solutions and iFuse 3D are trademarks of SIBONE, In. ©2024 SIBONE, Inc.
11495.032724 (product only)